Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to Aspergillus induced infection. Common Aspergillus infections include invasive Aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma (CPA). Invasive aspergillosis is uncommon and occurs primarily in immunocompromised people.

Click To Continue Reading on Aspergillosis Treatment Market

Chronic pulmonary aspergillosis is rare pulmonary disease, which increases symptoms of respiratory disorders such as asthma. According to a study published by European Respiratory Society (ERS) publications, in 2015, CPA is estimated to affect nearly 240,000 people in Europe. The most common form of CPA is Chronic Cavitary Pulmonary Aspergillosis (CCPA), which if left untreated can develop chronic fibrosing pulmonary aspergillosis. According to a statistics published by Centers for Disease Control and prevention, (CDC) an estimated 10% of individuals with asthma or cystic fibrosis experience an allergic reaction to aspergillus. ABPA is estimated to affect 2-15% of patients with cystic fibrosis and around 2% of all asthma patients.

Increasing prevalence of Aspergillosis and favorable government regulations are the major factors driving growth of the Aspergillosis treatment market. According to a study published in Journal of Fungi 2016, CPA is estimated to affect nearly three million people globally making it major health problem resulting in mortality and morbidity. Aspergillosis infection can be treated with antifungal and corticosteroids drugs. Corticosteroid drugs are prescribed for allergic bronchopulmonary aspergillosis treatment.

These drugs reduce inflammation and lowers respiratory symptoms such as coughing and wheezing. Some of the most frequently used drugs are methylprednisolone, prednisolone and prednisone. The U.S. Food & Drug Administration (FDA) approved various drugs for Aspergillosis infection treatment. For instance, in 2015, the U.S. FDA approved Isavuconazonium (Astellas Pharma), a prodrug form of Isavuconazole. Antifungal drugs are majorly used to treat invasive pulmonary Aspergillosis. Voriconazole, an antifungal drug is widely used due to less side effects and more effectiveness in comparison to other drugs. Itraconazole or Amphotericin B also treat the infection effectively. Caspofungin is used to treat infection, resistant to the other antifungals. Furthermore, antifungal drugs are sometimes used in combination with corticosteroids for treating ABPA. Surgeries may be required in some cases where aspergillomas are present leading to serious problems such as excessive bleeding. Antifungal drugs are generally not effective against aspergillomas, therefore surgery such as embolization is recommended. An aspergilloma is a solid mass of Aspergillus hyphae, mucus, fibrin, and other cellular debris, formed inside a pre-existing area of pulmonary cavity or scar.

The point-of-care platforms and technologies have significantly contributed to the transformation of healthcare landscape by bringing rapid diagnosis and monitoring tests closer, and making it more convenient for healthcare providers and patients. The test results obtained by electronic health records (EHR) assists in quicker diagnosis leading to faster decision making and early treatment onset. The POC tests and devices help alleviate various pain points of hospital-based healthcare providers who are under constant pressure for delivering cost and time efficient care that enhances treatment outcomes of patients. These rapid POC tests address the issues of latency in test results by facilitating accurate evidence-based triage and diagnostic decisions within fraction of time when compared to the time taken by centralized laboratory tests.

Click To Continue Reading @ PoC Platform & Technology Market

POC devices allow medical professionals to make decisions in patient’s vicinity, which results in significant healthcare delivery with faster results and immediate clinical management. The novel point-of-care tests (POCTs) offer diagnostic techniques for the prevention and treatment of infectious diseases such as HIV, Hepatitis B Virus, and chronic diseases such as diabetes, cancer, and cardiovascular disorders. According to the International Journal of Nanomedicine, in 2017, around 36.7 million people were affected by Human Immunodeficiency Virus (HIV) and around 400 million people were affected by viral hepatitis across the globe.

The survey also stated that with no reliable treatment for HIV infection, early diagnosis is a critical factor in managing AIDS patients, as it is a major cause for morbidity and mortality globally. Furthermore, the point-of-care technologies have enabled efficient monitoring of heart rate, inflammation threats, and heart failure that can potentially avert complications, reduce economic burden, and improve patient care across diverse medical and home care settings. According to the American Heart Association, cardiovascular diseases account for 17.3 million deaths per year globally and by 2030, around 23.3 million people are expected to die from CVD.

Increasing cancer and diabetes incidences is one of the major factors driving demand for point of care diagnostic tools and assays. Monitoring of glucose, hemoglobin, ketones, and other factors allows prevention and early detection of diabetes-related acute and chronic complications, and has a positive impact on the process of care and management of patients with diabetes. According to National Cancer Institute, in 2016, around 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the same disease. The number of people suffering from cancer is expected to rise to 19 million by 2024. According to the Global Diabetes Community, in 2017, around 422 million adults suffer from diabetes globally, where the number is expected to escalate to 642 million by 2040.

Systemic Lupus Erythematosus (SLE) is chronic autoimmune disorder. It is characterized by excess production of the antibodies that attacks body’s own cells and vital organs. Various symptoms associated with the disease includes joint pain, swelling, rashes over face (butterfly rash) and other body area, severe fatigue, hair loss, anemia, and Raynaud’s phenomenon etc. SLE can also affect vital body organs such as heart, kidney, lungs, and behavioral changes. Exact causes of the disease is unknown, however, hereditary and environmental factors could be lead to SLE.

Click To Continue Reading on Systemic Lupus Erythematosus Treatment Market

There is no direct cure available for SLE, however, symptomatic treatment can be administered to lower or eliminate symptoms associated with disease. Major classes of drugs commonly used are antimalarial agents such as chlorquine and hydrochlorquine; topical steroid cream for rashes; NSAIDS for joint pain; and fever steroidal medication such as glucocorticoids through IV or oral route and immunosuppressive agents to lower immune response from the antibodies.

Rise in incidence of SLE is one of major factors driving growth of the systemic lupus erythematosus treatment market. According to study published in the Expert Review of Clinical Immunology in 2017, the global incidence rate varied from about 0.3–23.7 per 100,000 person and the prevalence rates varied in the range from 6.5 to 178.0 per 100,000 people. Key companies are entering into collaborations for research and development in systemic lupus erythematosus, which is expected to support growth of the market.

For instance, in 2015, a genomic mapping company, 23andMe, Inc. collaborated with Pfizer, Inc. to study and understand the genetics of lupus thereby, to develop treatment for it. In 2012, Alliance for Lupus Research and Pfizer’s Centers for Therapeutic Innovation collaborated to discover new therapies for patients living with systemic lupus erythematosus. Increasing approvals for products for the treatment of SLE is another factor expected to aid in growth of the market. For instance, GlaxoSmithKline, in July 2017, received U.S.FDA approval for the subcutaneous form of its biologic drug belimumab for treatment of systemic lupus erythematosus. Clinical guidelines to include biologics in the treatment of systemic lupus erythematosus would further aid in market growth.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1540

Key Vendors:

GlaxoSmithKline Plc (GSK), F. Hoffmann-La Roche Ltd, Anthera Pharmaceuticals Inc., Bristol-Myers Squibb, Eli Lilly, Pfizer Limited, Merck KGaA, Immupharma Plc, Sanofi, Lycera Corporation, Aurinia Pharmaceuticals Inc., Mylan N.V., and Sandoz International GmbH.

A cold therapy unit is a machine designed to efficiently deliver cold therapy. It offers a much better alternative to traditional ice packs used for cold therapy.Cold therapy is the use of freezing temperatures to heal orthopedic injuries and pain. The cold temperature temporarily blocks blood supply on the application site by hindering nerve communication in the same area. Without a blood supply, the inflammation and the pain begin to reduce.Cold therapy works best when used consistently and via the right delivery methods. Rudimentary ice packs are really not ideal for the task. It is best to use a cold therapy unit for delivering cold therapy.The DesignCold therapy units consist of several components such as a pump, a tank, a healing pad, a connecting tube, and an adapter. These components work seamlessly to deliver cold temperature over wounds or injuries.The healing pad covers the injured area. The tank stores the water and ice. The pump aids the flow of water from the tank to the healing pad via the tube.Brands like IsoComforter use the patented Iso tube technology to design their cold therapy units. The use of this advanced technology helps to build machines that can deliver cold therapy safely and optimally. IsoComforter also ensures that its cold therapy units are easy to use. The use of self-priming pumps and easy mechanisms make it very easy to use IsoComforter machines.IsoComforter machines also have healing pads with ridge design to ensure optimal contact of the skin with the cold temperature. The ridges help to prevent burn injuries on the skin due to excessive freezing temperatures.UsesYou can use a cold therapy unit to heal orthopedic injuries of all kinds. Be it fractures, ligament tears, or ruptured tissues; you can use a cold therapy unit for consistent and efficient delivery of cold therapy.It is also helpful for speedy healing of patients post their back, knee, shoulder, and hip surgeries. Cold therapy helps patients regain range of motions in their joints sooner than expected post knee or shoulder injuries by experiencing reduced pain in a speedy manner. It helps them to begin their physical therapy without any delay.You can also use a cold therapy unit to treat sore and fatigued muscles.BenefitsA cold therapy unit helps users deliver cold therapy in a safe manner. For post-surgical healing, patients need a way to administer cold therapy easily, safely, consistent, and conveniently.Unlike ice packs, a cold therapy unit doesn’t drip water over incisions or open wounds.It is also easy to use a cold therapy unit. You can actually sit back and relax while the machine does its job. When you use IsoComforter machines, you won’t need to replenish ice in the tank very often. Ease of use of the machines enables the patients to administer cold therapy consistently. You can then experience speedy healing with natural therapy without resorting to pain medicines.